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Aim: Data on bone homoeostasis of children infected with human immunodeficiency virus (HIV),
at the time of the gain in bone mass, are very rare. To determine possible alterations in bone
metabolism, 13 prepubertal vertically HIV-infected children were studied. Methods: Viral load,
CD4 count, interleukin-6 (IL-6), growth hormone, insulin-like growth factor-I (IGF-I), IGF binding
protein-3 (IGFBP-3), acid-labile subunit (ALS), IGFBP-3 proteolysis, osteocalcin in blood and N-
terminal telopeptide of type I collagen in urine were determined. Lumbar spine bone mineral
density was examined by dual-energy X-ray absorptiometry. Results: Low osteocalcin levels were
found in all patients. Low IGF-I was found in only six children, who had low CD4 count and high
IL-6 levels, with normal levels of IGFBP-3 and ALS, absent IGFBP-3 proteolysis and decreased
bone mineral density, irrespective of viral load or growth.
Conclusion: Low serum osteocalcin levels appear to be an initial warning sign of possible altered
bone metabolism in HIV-infected children. However, only when the immune system becomes
more seriously compromised is bone loss measurable by bone densitometry.
Key words: Bone densitometry, bone metabolism, children, HIV infection, interleukin-6
G Zamboni, Pediatric Clinic, University of Verona, IT-37134 Verona, Italy (Tel. 39 45 8074469,
fax. 39 45 8200993, e-mail. Giorgio.Zamboni@univr.it)
Numerous factors may affect bone mineral density
(BMD) in childhood (1) and various potential effects on
skeletal homoeostasis may result from human immu-
nodeficiency virus (HIV) infection (2). Although the
probability of osteoblasts being infected in vivo by HIV
is very low (3), infection may affect bone metabolism
indirectly through decreased physical activity, malnu-
trition, fat malabsorption and endocrine diseases (4).
Moreover, HIV infection is characterized by enhanced
levels of proinflammatory cytokines that not only
enhance HIV replication and contribute to immunode-
ficiency, but also play an important role in bone
homoeostasis. Some cytokines, such as interleukin-6
(IL-6), may stimulate osteoclast and inhibit osteoblast
activity. Therefore, they play a pathogenic role in
enhancing bone resorption and inhibiting bone forma-
tion (5), and changes in their levels may result in altered
bone remodelling. In addition, a decrease in the serum
insulin-like growth factor (IGF) system may affect bone
remodelling in HIV-infected patients (6). In spite of
these potential effects, data on bone metabolism of
HIV-infected patients are conflicting, scarce in adults
(4, 7–9) and very rare in children (10–12).
On the basis of these observations, the present study
was undertaken to identify possible bone alterations in
HIV-infected children, because BMD increases during
growth and development.
Patients and methods
Thirteen prepubertal children vertically infected with
HIV (4M, 9F, mean age 7.8 2.9 y, range 4.08–
12.02 y) were enrolled. All were under antiretroviral
therapy with nucleoside analogues, but none of them
was receiving protease inhibitors. They had no severe
concomitant illnesses, nutritional alteration, recent
history of extended bed rest, previous diagnosis of
metabolic bone or endocrine diseases, liver insuffi-
ciency or renal failure, and had not used drugs with
known effects on bone metabolism. Disease stage was
classified using Centers for Disease Control and
Prevention criteria. Informed consent was obtained
from one parent or the guardian for each child; assent
was also obtained whenever possible. This study was
approved by the institutional ethics board.
Auxological parameters [weight, height, growth
velocity, body mass index (BMI)] were evaluated, as
well as blood HIV RNA level, CD4 cell count, IL-6,
growth hormone (GH) secretion [in both the basal
condition and after GH-releasing hormone (GH-RH)
stimulation], IGF-I, IGF binding protein-3 (IGFBP-3),
IGFBP-3 proteolytic activity, acid labile subunit (ALS),
osteocalcin and urine levels of N-terminal telopeptide
of type I collagen (NTx). Bone age (BA) and lumbar
spine BMD were also determined.
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Weight was measured to the nearest 0.1 kg using a
beam balance, with children wearing light clothing.
Height was measured without shoes by a Harpenden
stadiometer. Weight, height and growth velocity stan-
dard deviation scores (SDS) related to age were
calculated from the standards of Sempe´ et al. (13).
CD4 cell count was determined by flow cytometry.
The determination of plasma viral load was performed
using an ultrasensitive branched DNA assay (Chiron
Diagnostics, Emeryville, CA, USA) with a lower limit
of detection of 50 copies ml1.
Serum IL-6 levels were determined by enzyme-
linked immunosorbent assay (ELISA; Endogen, Wo-
burn, MA, USA) according to manufacturer’s protocol.
The sensitivity of the assay was 10 pg ml1.
Serum GH was measured using an immunometric
chemiluminescence assay (Diagnostic Products Cor-
poration, Los Angeles, CA, USA). The intra- and
interassay coefficients of variations (CVs) were
6.5% and 6.2%, respectively. The sensitivity was
0.0005 pmol l1. In this laboratory the response to GH
stimulation is considered normal when above
0.47 pmol l1. Serum IGF-I, IGFBP-3 and IGFBP-3
proteolytic activity were determined as described
previously (14).
Total serum ALS was measured using an enzyme-
linked immunosorbent assay (Diagnostic Systems Lab-
oratories, Webster, TX, USA). The intra-assay CVs for
mean serum concentrations of 26.9, 121.7 and
461.4 nmol l1 were 6.1%, 7.5% and 3.8%, respec-
tively. The interassay CVs for mean ALS concentra-
tions of 34.8, 124.8 and 475.6 nmol l1 were 8.6%,
2.8% and 8.9%, respectively. The sensitivity was
1.1 nmol l1.
Serum osteocalcin was measured by immunometric
chemiluminescence assay (Diagnostic Products Cor-
poration). The intra-assay CVs for mean osteocalcin
concentrations of 0.45, 2.26 and 14.02 nmol l1 were
2.8%, 2.8% and 4.5%, respectively. The interassay CVs
for mean osteocalcin concentrations of 0.45, 2.26 and
14.02 nmol l1 were 3.5%, 3.8% and 7.1%, respec-
tively. The sensitivity was 0.02 nmol l1.
Urine levels of NTx were measured by an enzyme
immunosorbent assay (Osteomark; Ostex, Seattle, WA,
USA). Urine specimens were collected between 10.00
and 12.00 h as the second voiding of the day. Assay
values were expressed in nanomoles bone collagen
equivalents per litre (nmol BCE l1). The sample results
from a single urine collection were normalized for urine
dilution by urine creatinine analysis and were reported
as nmoles BCE per mmole creatinine. The intra- and
interassay CVs were less than 9%. The sensitivity was
20 nmol BCE l1.
BA was determined blindly by the same observer,
according to the method of Greulich and Pyle (15) and
expressed in years. BMD at the lumbar spine was
measured by dual-energy X-ray absorptiometry (DXA
equipped with paediatric software; Lunar Corp., Madi-
son, WI, USA), as reported previously (16). The second,
third and fourth lumbar vertebrae were scanned in the
anteroposterior projection. Only the third lumbar
vertebra was also measured by lateral scan because of
possible interference with the assessment of the second
and fourth lumbar vertebrae by overlying ribs or iliac
crests, respectively. True volumetric BMD (BMDv)
was calculated, expressed in grams per cm3, taking the
vertebral body as an ellipsoid cylinder and dividing the
bone mineral content obtained by the lateral scan by
the body vertebral volume, calculated as: width/
2 depth/2 height. Vertebral dimensions (anterior
width, depth, and height) were found using software
data. The CV for duplicate measurements in normal
children at an interval of 1 wk was 1.0% for AP-BMD,
1.8% for L-BMD and 2.9% for BMDv. BMD SDS from
the normal population were calculated as: (measured
value – mean population value)/SD of the normal
population. The BMD SDS above and below the
average reference values were expressed as positive
and negative BMD SDS, respectively.
Blood IGF-I, IGFBP-3, ALS and osteocalcin levels,
urinary NTx levels and the bone densitometric data of
the patients were compared with those of a normal
prepubertal population of 198 subjects, aged 4–12 y
(94M, 104F), with bone age appropriate for chronolo-
gical age, BMI between 14.5 and 18 kg m2, normal
intake of calcium and phosphate, and normal physical
activity.
In normal subjects, IGF-I levels were 18.35
 3.8 nmol l1; IGFBP-3, 85.0 11.9 nmol l1; ALS,
212.5 82.7 nmol l1; osteocalcin, 9.44 2.26
nmol l1 in males and 10.08 2.32 nmol l1 in
females; and NTx, 363.4 195.5 nmol BCE mmol1
creatinine. BMDv normal values changed from
0.255 0.33 g cm3 in males and 0.267 0.03 g cm3
in females at 4 y of age to 0.293 0.05 in males and
0.313 0.03 g cm3 in females at 12 y of age.
The results are expressed as mean SD. Statistical
analysis was performed using unpaired Student’s t-test
with the Bonferroni correction when appropriate.
Results
Table 1 shows the auxological parameters of the
patients at the time of entry into the study. All
auxological parameters were generally adequate for
age and gender.
Table 2 shows immunological and endocrinological
parameters and BMDv in the patients. GH levels after
GH-RH stimulation showed normal GH secretion.
Serum osteocalcin levels in patients (2.89 2.55
nmol l1) were significantly lower (2.7 1.6 SDS)
than normal values for age and gender (p 0.05). Blood
IGF-I, IGFBP-3, ALS levels and urinary NTx levels
were higher in patients (IGF-I 25.7 26.1 nmol l1;
IGFBP-3 130.0 42.5 nmol l1; ALS 321.5 110.0
nmol l1; NTx 452.9 154.3 nmol BCE mmol1 crea-
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tinine) than in normal subjects, but the differences were
not statistically significant.
Regarding BMDv, 6 out of 13 patients showed
negative BMDv SDS values (1.0 0.8); 2 out of the
6 suffered from severe bone pains, and 1 had sponta-
neous fracture of the left clavicle. In these 6 patients,
IGF-I levels (10.02 3.4 nmol l1; 1.12 0.8 SDS)
and CD4 count (499.2 87.1 106 cells l1) were
significantly lower than in 7 patients with positive
BMDv SDS (IGF-I 39.2 18.3 nmol l1, 1.85 1.5
SDS; CD4 896.7 170.6 106 cells l1; BMDv SDS
1.3 0.6; p 0.05 for all parameters). IGFBP-3 and
ALS levels were also lower in these patients (IGFBP-3
110.05 22.5 nmol l1, 1.33 0.8 SDS; ALS 285.9
 84.5 nmol l1, 0.63 0.55 SDS) than in 7 patients
with positive BMDv SDS (IGFBP-3 147.17
37.2 nmol l1, 2.6 0.9 SDS; ALS 376.3
98.3 nmol l1, 1.8 0.9 SDS), but the differences were
not statistically significant. In contrast, in patients with
negative BMDv SDS values, IL-6 levels were much
higher (562.5 356.8 pg ml1; p 0.05) than in pa-
tients with positive BMDv SDS, in which they were
undetectable. In addition, urinary NTx levels were
higher in these 6 patients (510.3 144.8 vs
403.7 113.5 nmol BCE mmol1 creatinine), but the
difference was not statistically significant. The analysis
of IGBP-3 showed no significant proteolytic activity in
any patient.
No significant correlation was found in the patients
between osteocalcin and IGF-I, IGFBP-3 and ALS, and
between osteocalcin and BMD.In contrast, BMDvvalues
were positively correlated with IGF-I levels and CD4
count and negatively with IL-6 levels. Figure 1 shows
significant positive correlations among BMDv SDS and
IGF-I SDS levels (r = 0.746) and CD4 cell count
(r = 0.809) and a negative correlation between BMDv
and IL-6 levels (r = 0.742); p 0.05 in all cases.
Discussion
All of the HIV-infected children in this study had
Table 1. Auxological parameters in the patients.
Age Weight Height BMI Growth velocity Bone age
Patient Gender (y) SDS SDS (kg m2) SDS (y)
1 F 12.02 1.7 1.1 19.86 0.20 11.0
2 M 6.51 1.4 1.6 14.48 1.10 5.5
3 F 11.89 1.5 1.7 18.73 0.50 10.5
4 M 7.69 3.1 2.4 18.38 0.65 7.0
5 M 4.44 1.0 0.9 15.72 1.00 3.5
6 F 11.49 3.3 0.5 24.86 0.80 10.5
7 F 4.08 1.3 1.5 15.16 0.20 3.5
8 F 6.09 2.1 1.0 17.16 1.60 6.0
9 F 8.40 0.2 1.4 14.13 1.00 8.5
10 F 10.54 0.7 0.4 18.79 1.50 10.0
11 F 5.88 1.0 0.1 17.04 0.50 6.0
12 M 9.08 0.6 0.5 16.96 1.60 9.0
13 F 4.16 1.5 1.2 16.40 1.50 3.0
Mean SD 7.8 2.9 1.1 1.4 0.5 1.2 17.51 2.81 0.39 1.02 7.2 2.9
Range 4.08 to 12.02 1.4 to 3.3 1.6 to 2.4 14.13 to 24.86 1.6 to 1.0 3 to 11
Table 2. Immunological and endocrinological parameters, and volumetric bone mineral density (BMDv) in the patients.
Viral load CD4 count IL-6 GH peak IGF-I OC BMDv BMDv
Patient CDC class (copies ml1) ( 106 cells l1) (pg ml1) (pmol l1) (nmol l1) (nmol l1) (g cm3) SDS
1 A2 23450 1220 UD 0.53 57.6 0.53 0.361 1.3
2 C3 47639 350 870 0.93 12.7 1.47 0.210 2.0
3 A1 8931 750 UD 0.68 68.0 6.30 0.354 1.2
4 B2 13448 506 655 1.03 9.2 7.90 0.235 1.6
5 B1 7630 485 720 1.00 9.2 2.20 0.232 0.7
6 A1 2794 727 UD 0.47 19.0 0.55 0.350 1.1
7 A1 106377 486 890 0.50 4.1 3.90 0.244 0.8
8 B2 15450 977 UD 0.64 41.7 1.52 0.331 1.7
9 A2 23450 870 UD 2.28 27.1 1.80 0.298 0.2
10 B1 5067 605 190 0.85 11.5 1.20 0.238 1.5
11 A1 13918 563 50 0.96 13.4 2.70 0.256 0.9
12 A2 18918 793 UD 1.04 22.5 6.90 0.345 2.1
13 A2 44580 940 UD 2.09 38.5 0.65 0.308 1.5
Mean SD 25512 27920 713.2 245.5 1.00 0.56 25.7 20.1 2.89 2.55 0.289 0.055 0.123 1.42
CDC: Centers for Disease Control; IL-6: interleukin-6; GH: growth hormone; IGF-I: insulin-like growth factor-I; OC: osteocalcin; SDS: standard
deviation score; UD: undetectable.
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significantly lower serum osteocalcin levels and slightly
higher urinary NTx than controls. Osteocalcin is an
indirect parameter of bone formation and NTx of bone
resorption. However, a reduced BMD was found in only
6 out of 13 patients, who had a reduced CD4 count, low
circulating IGF-I levels despite normal basal and
stimulated GH levels, and enhanced IL-6 levels,
irrespective of viral load or growth. Alterations in bone
markers and bone mineral loss have been reported
previously in HIV infection (8–12), but the HIV-
infected children (10–12, 17) were studied nearly
exclusively in the areas of BMD and of bone metab-
olism. This study presents new data in the area of GH/
IGF-I and immune systems, supporting a relationship
between HIV infection and disturbed bone metabolism.
IGF-I is an important regulator of osteoblast and
osteoclast activity, modulating osteoblast–osteoclast
interactions as a coupling agent in the bone remodelling
process. Originally, postnatal longitudinal growth was
thought to be controlled by GH and mediated by
circulating IGF-I produced by the liver (18); however,
recent experiments in mice have shown normal post-
natal and peripubertal growth, despite the deletion of
the IGF-I gene, the loss of liver IGF-I production and
the reduction in circulating IGF-I (19). Recently,
importance has been placed upon an autocrine/paracrine
role for skeletal IGF-I (18), which is available in the
bone matrix and from activated osteoblasts. Never-
theless, the correlation between the increase in skeletal
and serum IGF-I levels and the increase in bone mass in
children is well known, although in the long bones IGF-
I seems to be a major determinant of the cross-sectional
area of cortical bone, poorly influencing bone density
(20). Low IGF-I levels could be due to a break in the
circulating ternary complex (21), comprised of IGF-I,
ALS and IGFBP-3, by IGFBP-3 proteolysis. Increased
IGFBP-3 proteolysis by specific proteases has been
described in HIV-infected adults with advanced disease
(22) and in HIV-infected children who failed to thrive
(23). However, the patients in the present study had
generally normal nutrition and growth, and those with
low serum IGF-I showed normal values of ALS and
IGFBP-3 and absent IGFBP-3 proteolysis.
In HIV infection, as well as in children’s chronic
inflammation and infection with normal GH production
and decreased IGF-I levels (24), there is an altered
expression of cytokines, as well as an overproduction of
proinflammatory IL-6 (25), which appear to be relevant
to the inflammatory process and in influencing inter-
mediary metabolism, including a negative interference
with IGF-I activity or secretion (6, 26). Because
circulating IGF-I is produced mainly in the liver and
IL-6 is notably involved in the regulation of gene
transcription during inflammation, it may be hypothe-
sized that overproduction of IL-6 acts negatively on
liver IGF-I gene expression and therefore is responsible
for decreased circulating IGF-I, with a possible limited
role for the growth factor in bone remodelling. IL-6
hypersecretion, together with low IGF-I levels and low
growth velocity (6) or poor growth and reduced energy
intake (26), has already been reported in HIV-infected
children. In 6 out of 13 patients in the present study, IL-
6 levels inversely correlated with IGF-I levels, and CD4
count, did not correlate with viral load or growth
impairment.
HIV could reduce bone mineralization by enhancing
production of IL-6, an autocrine/paracrine factor which
stimulates osteoclast formation and activity, and by
reducing the skeletal production of IGF-I. IL-6 over-
production by some viruses has also been implicated in
some pathological conditions characterized by bone
loss (27). Therefore, increased activity of cytokines, as
well as the recently identified osteoprotegerin that
promotes osteoclast activation (28), may also play an
Fig. 1. Correlation between volumetric bone mineral density standard deviation scores (BMDv SDS), insulin-like growth factor-I SDS (IGF-I
SDS), CD4 (106 cells l1) and interleukin-6 (IL-6, pg ml1) in the patients.
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important role in mediating disturbed bone metabolism
during HIV infection.
In conclusion, a low serum osteocalcin level appears
to be an initial warning sign of possible altered bone
metabolism. Only when the immune system is more
seriously compromised, as indicated by high IL-6 levels
and a more severe decrease in CD4 count, does bone
loss become measurable by bone densitometry. HIV
infection itself, by enhancing cytokine production,
appears to be responsible for altered bone metabolism.
These results need to be confirmed in a larger cohort
of patients, both to demonstrate conclusively that HIV
infection could result in a possible bone disorder at a
very critical period of life with respect to reaching
maximal peak bone mass, and to develop treatment
strategies to preserve maximal bone mass in patients at
risk for reduced BMD.
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